ArticleEmerging microbes & infections2023
SaeR as a novel target for antivirulence therapy against
Article in Emerging microbes & infections, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Elucidating the Staphylococcus aureus TSST-1 Regulatory Network as a Response to Vaginal pH.Molecular microbiology · 2026Article
- Synthesis and Biological Evaluation of Novel C-28 Chloroacetamide-Modified Ursolic Acid Derivatives as Antibacterial Agents.Microorganisms · 2026Article
- Cucurbitacin B mitigatesJournal of pharmaceutical analysis · 2026Article
- Antimicrobial efficacy ofMicrobiology spectrum · 2026Article
- Daphnoretin as a potent sortase A inhibitor effectively disarms drug-resistant Staphylococcus aureus infections.World journal of microbiology & biotechnology · 2026Article
- Global emergence and evolution ofmSystems · 2026Article
- A novel SaeS-targeting antivirulence antagonist screened against methicillin-resistantFrontiers in cellular and infection microbiology · 2026Article
- A comprehensive review of emerging therapeutic strategies against methicillin-resistantFrontiers in microbiology · 2026Review
- Novel antimicrobial 3-phenyl-4-phenoxypyrazole derivatives target cell wall lipid intermediates with low mammalian cytotoxicity.Scientific reports · 2025Article
- In Vitro Analysis of Interactions BetweenAntibiotics (Basel, Switzerland) · 2025Article
- DisarmingPathogens (Basel, Switzerland) · 2025Review
- TheMicroorganisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.